Check out our comprehensive educational activities here

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

In this activity, Dr. Eunice Wang explains the adverse events associated with liposomal cytarabine and daunorubicin and how to manage them on an outpatient basis.

Published on December 7, 2020 in Treatment

What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?

Dr. Wang describes how she determines upfront therapy for a patient with newly diagnosed secondary AML.

Published on November 30, 2020 in Treatment

Expert Opinions on Common Clinical Challenges in AML

In this newsletter, three experts address common clinical challenges practitioners face in AML such as maintenance regimens for FLT3-mutated AML or MRD-eradicating strategies.

Published on October 14, 2020 in Treatment

Key Updates from ASCO 2020 and EHA 2020: Experts Discuss Data and Implications Important to Clinical Practice

In this newsletter, Dr. Daver and Dr. Perl discuss their choices of the most important data to come out of the ASCO 2020 and EHA 2020 meetings in AML and their clinical implications.

Published on October 7, 2020 in Treatment

New Advances in AML Discussion

In this activity, three experts will discuss advances in therapeutic strategies for individual patients with newly diagnosed and relapsed/refractory AML.

For an educational activity on New Advances in AML please click here

Published on July 10, 2020 in Treatment

High Rate of IDH1 Mutation Clearance and MRD Negativity in Patients with IDH1 Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Join Dr. Stein as he explains administering ivosidenib and azacitidine together in a safe manner, and how this could impact practice for patients with newly diagnosed AML.

Published on May 27, 2020 in Treatment

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?

In this activity, Dr. Perl explains one of the most potent and selective FLT3 inhibitors developed and where it will fit in the treatment landscape if approved.

Published on May 6, 2020 in Treatment

How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?

It is important to screen for FLT3 mutations in patients who have relapsed/refractory AML. Join Dr. Perl as he covers the results of the phase 3 ADMIRAL trial and how this will impact practice.

Published on May 6, 2020 in Treatment

Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Watch Dr. Daver discuss the potential of venetoclax in combination with traditional induction chemotherapy for a younger and fitter AML population.

Published on April 22, 2020 in Treatment

How to utilize and sequence new drugs in the treatment of AML

With the approval of new drugs that target specific genetic mutations, the treatment of AML has become complicated. In this activity, Dr. Stein explains how to navigate the combinations and sequences.

Published on April 10, 2020 in Treatment